Jing Zeng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1143619/publications.pdf

Version: 2024-02-01

61	1,061	430874	454955
papers	citations	18 h-index	30 g-index

62	62	62	1549
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. Advances in Radiation Oncology, 2022, 7, 100858.	1.2	3
2	Multitask Learning Radiomics on Longitudinal Imaging to Predict Survival Outcomes following Risk-Adaptive Chemoradiation for Non-Small Cell Lung Cancer. Cancers, 2022, 14, 1228.	3.7	20
3	PSMA PET: Enabling More Dose to Less Volume?. International Journal of Radiation Oncology Biology Physics, 2022, 113, 255.	0.8	0
4	Consensus Statement on Proton Therapy in Mesothelioma. Practical Radiation Oncology, 2021, 11, 119-133.	2.1	11
5	Treatment Intensification in Locally Advanced/Unresectable NSCLC Through Combined Modality Treatment and Precision Dose Escalation. Seminars in Radiation Oncology, 2021, 31, 105-111.	2.2	3
6	Radiation and Modulation of the Tumor Immune Microenvironment in Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 133-139.	2.2	6
7	Radiation Treatment of Nonâ€“Small Cell Lung Cancer. Seminars in Radiation Oncology, 2021, 31, 95-96.	2.2	0
8	Tumor control probability in hypofractionated radiotherapy as a function of total and hypoxic tumor volumes. Physics in Medicine and Biology, 2021, 66, 125010.	3.0	2
9	Reliability of Quantitative 18F-FDG PET/CT Imaging Biomarkers for Classifying Early Response to Chemoradiotherapy in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer. Clinical Nuclear Medicine, 2021, 46, 861-871.	1.3	9
10	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. Advances in Radiation Oncology, 2021, 7, 100857.	1.2	0
11	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. Translational Gastroenterology and Hepatology, 2020, 5, 21-21.	3.0	2
12	Scanning Beam Proton Therapy versus Photon IMRT for Stage III Lung Cancer: Comparison of Dosimetry, Toxicity, and Outcomes. Advances in Radiation Oncology, 2020, 5, 434-443.	1.2	9
13	Rectal Hydrogel Spacer Improves Late Gastrointestinal Toxicity Compared to Rectal Balloon Immobilization After Proton Beam Radiation Therapy for Localized Prostate Cancer: A Retrospective Observational Study. International Journal of Radiation Oncology Biology Physics, 2020, 108, 635-643.	0.8	17
14	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 158-173.	2.1	111
15	Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy. British Journal of Radiology, 2019, 92, 20190174.	2.2	14
16	Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging. Clinical Cancer Research, 2019, 25, 5027-5037.	7.0	10
17	Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Practical Radiation Oncology, 2019, 9, 280-288.	2.1	31
18	An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting. Clinical and Translational Radiation Oncology, 2019, 15, 83-92.	1.7	4

#	Article	IF	Citations
19	Proton therapy for thymic malignancies: multi-institutional patterns-of-care and early clinical outcomes from the proton collaborative group and the university of Florida prospective registries. Acta OncolÃ³gica, 2019, 58, 1036-1040.	1.8	12
20	Bladder Cancer Multidisciplinary Clinic (BCMC) Model Influences Disease Assessment and Impacts Treatment Recommendations. Bladder Cancer, 2019, 5, 289-298.	0.4	7
21	Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience. Advances in Radiation Oncology, 2019, 4, 70-78.	1.2	5
22	Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2003-2004.	1.6	4
23	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 180-188.	2.8	28
24	Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer. Translational Lung Cancer Research, 2018, 7, 114-121.	2.8	32
25	Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 122-133.	2.8	9
26	Heart Dose and Outcomes in Radiation Treatment for Esophageal Cancer. Cureus, 2018, 10, e2378.	0.5	10
27	Volume dependence in hypoxiaâ€targeted dose escalation. Medical Physics, 2018, 45, 5325-5331.	3.0	6
28	Radiation oncology resident training in patient safety and quality improvement: a national survey of residency program directors. Radiation Oncology, 2018, 13, 186.	2.7	11
29	Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes. Radiation Oncology, 2018, 13, 179.	2.7	4
30	Utilizing simulated errors in radiotherapy plans to quantify the effectiveness of the physics plan review. Medical Physics, 2018, 45, 5359-5365.	3.0	7
31	Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1255-1264.	0.8	17
32	Does Neutron Radiation Therapy Potentiate an Immune Response to Merkel Cell Carcinoma?. International Journal of Particle Therapy, 2018, 5, 183-195.	1.8	15
33	Proton therapy in non-small cell lung cancer. Translational Lung Cancer Research, 2018, 7, 103-105.	2.8	0
34	A survey of residentsâ€™ experience with patient safety and quality improvement concepts in radiation oncology. Practical Radiation Oncology, 2017, 7, e253-e259.	2.1	11
35	Theoretical effectiveness of cell survival in fractionated radiotherapy with hypoxiaâ€targeted dose escalation. Medical Physics, 2017, 44, 1975-1982.	3.0	10
36	SBRT in five fractions. International Journal of Radiation Oncology Biology Physics, 2017, 97, 652-653.	0.8	0

#	Article	IF	Citations
37	Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry. Strahlentherapie Und Onkologie, 2017, 193, 410-418.	2.0	24
38	Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy. Medical Physics, 2017, 44, 3418-3429.	3.0	55
39	Dose Escalation Optimization in Patients With Locally Advanced Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2017, 3, 1365.	7.1	2
40	Are we making an impact with incident learning systems? Analysis of quality improvement interventions using total body irradiation as a model system. Practical Radiation Oncology, 2017, 7, 418-424.	2.1	8
41	The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients. Advances in Radiation Oncology, 2017, 2, 192-196.	1.2	12
42	Evaluation of near-miss and adverse events in radiation oncology using a comprehensive causal factor taxonomy. Practical Radiation Oncology, 2017, 7, 346-353.	2.1	24
43	Multi-Institutional Experience of Stereotactic Ablative Radiation Therapy for Stage I Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 97, 362-371.	0.8	78
44	Proton Therapy for Malignant Pleural Mesothelioma: A Three Case Series Describing the Clinical and Dosimetric Advantages of Proton-Based Therapy. Cureus, 2017, 9, e1705.	0.5	10
45	Targeting safety improvements through identification of incident origination and detection in a near-miss incident learning system. Medical Physics, 2016, 43, 2053-2062.	3.0	22
46	The effectiveness of pretreatment physics plan review for detecting errors in radiation therapy. Medical Physics, 2016, 43, 5181-5187.	3.0	40
47	Mentorship Programs in Radiation Oncology Residency Training Programs: A Critical Unmet Need. International Journal of Radiation Oncology Biology Physics, 2016, 94, 27-30.	0.8	32
48	Influence of planning time and treatment complexity on radiation therapy errors. Practical Radiation Oncology, 2016, 6, 187-193.	2.1	14
49	Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer. Strahlentherapie Und Onkologie, 2016, 192, 913-921.	2.0	25
50	Standardizing dose prescriptions: An ASTRO white paper. Practical Radiation Oncology, 2016, 6, e369-e381.	2.1	30
51	Overview of the Novel and Improved Pulmonary Ventilation-Perfusion Imaging Applications in the Era of SPECT/CT. American Journal of Roentgenology, 2016, 207, 1307-1315.	2.2	16
52	Interrater reliability of a near-miss risk index for incident learning systems in radiation oncology. Practical Radiation Oncology, 2016, 6, 429-435.	2.1	6
53	Sestrin2 protects the myocardium against radiation-induced damage. Radiation and Environmental Biophysics, 2016, 55, 195-202.	1.4	20
54	Best practices for safety improvement through high-volume institutional incident learning: lessons learned from 2Âyears. Journal of Radiation Oncology, 2016, 5, 323-333.	0.7	3

#	Article	IF	Citations
55	Sodium glycididazole enhances the radiosensitivity of laryngeal cancer cells through downregulation of ATM signaling pathway. Tumor Biology, 2016, 37, 5869-5878.	1.8	9
56	Can emergent treatments result in more severe errors?: An analysis of a large institutional near-miss incident reporting database. Practical Radiation Oncology, 2015, 5, 319-324.	2.1	9
57	Tumor length as a prognostic factor in esophageal cancer management. Journal of Radiation Oncology, 2015, 4, 71-77.	0.7	2
58	Metrics of success: Measuring impact of a departmental near-miss incident learning system. Practical Radiation Oncology, 2015, 5, e409-e416.	2.1	40
59	Measurable improvement in patient safety culture: A departmental experience with incident learning. Practical Radiation Oncology, 2015, 5, e229-e237.	2.1	42
60	Combination of stereotactic ablative body radiation with targeted therapies. Lancet Oncology, The, 2014, 15, e426-e434.	10.7	32
61	Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses. BioMed Research International, 2013, 2013, 1-8.	1.9	66